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Graves’ disease (GD) is an autoimmune oligogenic disorder with a strong hereditary 
component. Several GD susceptibility genes have been identified and confirmed during 
the last two decades. However, there are very few studies that evaluated susceptibility 
genes for GD in specific geographic subsets. Previously, we mapped a new locus on 
chromosome 3q that was unique to GD families of Italian origin. In the present study, we 
used association analysis of single-nucleotide polymorphism (SNPs) at the 3q locus in a 
cohort of GD patients of Italian origin in order to prioritize the best candidates among the 
known genes in this locus to choose the one(s) best supported by the association. DNA 
samples were genotyped using the Illumina GoldenGate genotyping assay analyzing 690 
SNP in the linked 3q locus covering all 124 linkage disequilibrium blocks in this locus. 
Candidate non-HLA (human-leukocyte-antigen) genes previously reported to be associ-
ated with GD and/or other autoimmune disorders were analyzed separately. Three SNPs 
in the 3q locus showed a nominal association (p < 0.05): rs13097181, rs763313, and 
rs6792646. Albeit these could not be further validated by multiple comparison correction, 
we were prioritizing candidate genes at a locus already known to harbor a GD-related 
gene, not hypothesis testing. Moreover, we found significant associations with the thyroid- 
stimulating hormone receptor (TSHR) gene, the cytotoxic T-lymphocyte antigen-4 
(CTLA-4) gene, and the thyroglobulin (TG) gene. In conclusion, we identified three SNPs 
on chromosome 3q that may map a new GD susceptibility gene in this region which is 
unique to the Italian population. Furthermore, we confirmed that the TSHR, the CTLA-4, 
and the TG genes are associated with GD in Italians. Our findings highlight the influence 
of ethnicity and geographic variations on the genetic susceptibility to GD.
Keywords: graves’ disease, thyroid diseases, genetic predisposition to disease, snP association study, italian 
patients
inTrODUcTiOn
Graves’ disease (GD) is one of the most common autoimmune endocrine disorders characterized by 
goiter, hyperthyroidism and, in 10–25% of patients, ophthalmopathy (1, 2). GD is an antibody-mediated 
autoimmune disease, in which the pathogenic antibodies stimulate the thyroid-stimulating hormone 
(thyrotropin, TSH) receptor resulting in the clinical syndrome of goiter and hyperthyroidism. The 
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pathogenesis of GD involves breakdown of central and peripheral 
tolerance, infiltration of the thyroid with thyroid-directed T-cells 
that escaped tolerance, and activation of B-cells to secrete TSH 
receptor (TSHR) stimulating antibodies (3).
While the exact etiology of GD has not been pinpointed 
yet, accumulating data, mainly obtained in twin studies, sup-
port a solid genetic predisposition to the disease, although the 
penetrance of the genetic determinants is about 22–35% (based 
on monozygotic twin concordance rates) (4–6). Several GD 
susceptibility genes have been identified and confirmed through 
linkage and association studies during the last three decades, 
including immune regulatory genes HLA-DR, (human leukocyte 
antigen – D related) cluster of differentiation 40 (CD40), CTLA-4, 
protein tyrosine phosphatase non-receptor type 22 (PTPN22), 
interleukin-2 receptor alpha chain (CD25), and thyroid-specific 
genes TSHR and TG (7). Moreover, several susceptibility genes for 
Graves’ ophthalmopathy have been proposed over the years based 
on small case–control association studies. These include CTLA-4, 
tumor necrosis factor-α (TNF-α), intercellular adhesion mol-
ecule-1 (ICAM-1), interferon-γ (IFN-γ) (8), insulin-like growth 
factor-1 receptor (IGF-1R) (9), suppressor of cytokine signaling 
3 (SOCS3) (10), thyroid peroxidase (TPO) (11), calsequestrin 1 
(CASQ1) (12), cysteine-rich angiogenic inducer 61 (CYR61), zinc 
finger protein 36 C3H type homog mouse (ZFP36), and stearoyl-
coenzyme A desaturase (SCD) (13). However, none of the Graves’ 
ophthalmopathy specific genes have been confirmed.
Ethnicity and geographic variations influence the genetic sus-
ceptibility to GD. Previous studies demonstrated in Caucasian 
populations a positive and a negative association of GD with the 
serologically defined HLA DR3 and DR5 groups, respectively 
(14, 15). HLA-DRB1*0301 gave the highest positive predictive 
value for GD (15). HLA genes have been shown to be associated 
with GD in non-Caucasian populations as well, though the asso-
ciated alleles were different from those observed in Caucasians 
(7, 16–18). For instance, the HLA-DRB1*0405/DQB1*0401 and 
the DRB3*020/DQA1*0501 haplotypes have been directly linked 
to GD in Asians (19) and in African-American (20) subjects, 
respectively. Notably, ethnic influences have been reported 
also for non-MHC genes; indeed linkage analysis in Caucasian 
families from different geographic regions showed different 
influences of the CTLA-4 gene on GD development (21, 22), 
suggesting that even within the same ethnic group, geographic 
variations can have a strong effect on susceptibility to disease. 
Similarly, a recent study indicated that genetic polymorphisms 
at CD25, a gene that is associated with GD in Caucasians, do not 
exert a significant genetic effect on the development of GD in 
the Chinese Han population (23). Also, significant ethnic differ-
ences in the distribution of two germline TSHR polymorphisms 
(P52T and D727E) were found among the Chinese, Malays, and 
Indians (24).
Intriguingly, epidemiological surveys from various, mostly 
iodine sufficient, populations have shown a relatively compara-
ble incidence of GD across Caucasian populations in different 
geographic regions (approximately 20–25/100,000/year). The 
comparable prevalence and incidence of GD in geographically 
distinct Caucasian populations may indicate that these popula-
tions share at least some of their susceptibility genes for GD, albeit 
unique GD genes for different populations must exist too (25). 
Nevertheless, there are very few studies that analyzed suscepti-
bility genes for GD in specific geographic subsets of Caucasian 
GD patients. We have previously performed linkage analyses in a 
large dataset of multiplex GD families. Within our large dataset of 
GD families, an Italian subset of GD families did not show linkage 
to the CD40 gene/locus on chromosome 20q in contrast to all 
other Caucasian populations we studied. Moreover, we mapped 
a new locus on chromosome 3q that was unique to the Italian 
subset of our GD families (26). These data suggest that there are 
unique susceptibility gene/loci within Caucasian GD patients, as 
determined by our subset of Italian GD families, and that distinct 
genes predispose to GD in different subsets of patients.
Our previous results demonstrate the importance of identify-
ing subsets of patients within large datasets in order to map genes 
that may be subset-specific. Therefore, the goal of the present 
study was to fine map the 3q locus and evaluate known GD 
susceptibility genes in a cohort of GD patients of Italian origin.
MaTerials anD MeThODs
study subjects
The project was approved by the Mount Sinai School of Medicine 
Institutional Review Board. We analyzed Caucasian GD patients 
of Italian origin. GD was diagnosed by (1) documented clinical 
and biochemical hyperthyroidism requiring treatment and (2) 
presence of TSH receptor antibodies and/or diffusely increase 
131I uptake in the thyroid gland.
genotyping
DNA was extracted from whole blood using the Puregene kit 
(Gentra Systems, Minneapolis, MN, USA). DNA samples were 
genotyped using the Illumina GoldenGate genotyping assay as 
previously described (27). The GoldenGate single-nucleotide 
polymorphism (SNP) genotyping platform uses a discriminatory 
DNA polymerase and ligase to interrogate many SNPs simultane-
ously. The protocol is automated allowing high throughput and 
minimal errors. The GoldenGate genotyping assay utilized the 
BeadArray Reader. The GoldenGate assays were designed to 
analyze SNPs both in the linked locus on chromosome 3 and in a 
panel of GD candidate genes.
Fine Mapping of the chromosome 
3q locus
The chromosome 3q locus spans about 14  Mb and was fine 
mapped using a panel of 690 SNPs. Since the linkage analysis 
showed that there was a gene in the region, our goal in association 
mapping was to prioritize the best candidates among the known 
genes in this locus to choose the one(s) best supported by the 
association. Markers for fine mapping 3q were selected from 
the Illumina Infinium Human1M BeadChip panel leveraging 
the pre-selection by Illumina of markers focused on haplotype 
tagging and maximal allele frequency in the CEU population. The 
SNPs selected were sufficient to capture all alleles with an r2 > 0.8. 
The mean max r2 for our SNPs was 0.987. Therefore, our 690 SNPs 
gave more than sufficient coverage of the 3q locus.
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Case–control association analyses for markers within the 3q 
locus were performed using the UNPHASED computer package.1 
UNPHASED (28, 29) is a suite of programs for association analy-
sis of multilocus haplotypes from unphased genotype data. We 
used the Cocaphase program (within the UNPHASED package) 
for case–control association analyses performing the χ2 test on all 
690 SNPs simultaneously. The odds ratio (OR) was calculated by 
the method of Woolf (30).
linkage Disequilibrium analysis
Linkage disequilibrium (LD) analysis was performed for the 3q 
locus using the Haploview program2 using SNP genotypes from 
the HapMap database (31). Haplotype analysis and haplotype 
association analysis of SNPs rs13097181, rs7633131, and 6792646 
was performed with Haploview using our Italian GD and Italian 
controls genotypes.
candidate gene analysis
Non-HLA genes that have been previously reported to be associ-
ated with GD and/or other autoimmune disorders were analyzed 
separately using the χ2 test. These candidate genes included 
TSHR, TG, CTLA-4, CD40, interleukin 23 receptor (IL23R), 
CD25, PTPN22, forkhead box P3 (FOXP3), interferon regulatory 
factor 5 (IRF5), and toll-like receptor 4 (TLR4) genes (32–37).
Power calculations
Power calculations were performed using the CDC simulation 
software (Epi-Info, 7.1.3.3, CDC, Atlanta) (38). We assumed the 
population frequency of the susceptibility SNP allele to be ≥10% 
since we tested only common variants, and we used the gamete 
numbers since we performed allelic associations (39). The power 
calculations demonstrated that our dataset of 333 GD patients 
(666 chromosomes) and 117 controls (234 chromosomes) will 
give the study 80% power to detect a difference between the 
patients and the controls resulting in ORs of ≥2.0 with an alpha 
of 0.05. Therefore, our study was sufficiently powered to detect 
functionally significant differences between patients and controls.
resUlTs
characteristics of the italian gD 
Population
We studied 333 Caucasian patients with GD of Italian origin. The 
average age at diagnosis was 40.0 ± 13.8 years (range 13–75 years), 
and there were 249 female and 84 male patients. The average 
age at ascertainment was 47.1 ±  13.7, and the average disease 
duration was 7.1  years. Additionally, 180 patients (54%) had 
goiter, 154 patients (46%) had Graves’ ophthalmopathy, and in 
45 patients (14%), the ophthalmopathy status could not be con-
firmed. Control individuals of Italian origin (n = 117) had normal 
thyroid function, were negative for thyroid autoantibodies, and 
had no personal or family history of thyroid disease. There were 
64 (55%) women and 53 men (45%). They were all over 18 years of 
1 http://unphased.sourceforge.net/
2 http://broad.mit.edu/mpg/haploview/
age. However, the precise age at ascertainment was not available 
for all the controls.
Fine Mapping of the chromosome 3q 
locus and haplotype analysis
Figure 1 shows the results of association analyses of the 690 SNPs 
used to fine map the chromosome 3q locus that is linked with 
GD in patients of Italian origin. Three SNPs showed a significant 
association: rs13097181 (p =  3.7  ×  10−3, OR: 2.0), rs7633131 
(p = 7.7 × 10−3, OR: 1.7), and rs6792646 (p = 7.8 × 10−3, OR: 1.5). 
LD analysis showed that the 3q locus contained 124 LD blocks. 
If we were testing the hypothesis that there is a GD gene in the 
region, it would have been necessary to correct for multiple test-
ing which would make the associations not significant. However, 
we were not testing the hypothesis of a GD gene in this locus. 
Rather our goal was to prioritize candidate genes at a locus 
already known to harbor a GD-related gene, and the p-values 
were only used to prioritize.
Haplotype analysis performed using Haploview for SNPs 
rs13097181, rs7633131, and rs6792646 (using either the geno-
types in our cohort or the HapMap genotypes) revealed that there 
was no LD between these three SNPs due to the large distances 
between them (5.3  Mb between rs13097181 and rs7633131; 
1.8 Mb between rs7633131 and rs6792646). Therefore, no haplo-
types were identified for these three SNPS, and no combination 
of alleles of these three SNPs was associated with GD.
candidate gene analysis
Several genes have been previously reported to be associated with 
GD in Caucasians and other ethnic groups (5, 40). We investigated 
a panel of genes previously shown to be linked with GD as well as 
genes associated with other autoimmune diseases (e.g., IRF5 and 
TLR4, see Table 1). Among the candidate genes tested, we found 
associations with the TSHR gene (p = 3.94 × 10−6), the CTLA-4 
gene (p = 1 × 10−3), and the TG gene (p = 0.029).
DiscUssiOn
A strong hereditary component in the pathogenesis of GD has 
long been recognized (41, 42). The inheritance of GD is complex, 
involving multiple genes with variable penetrance, and envi-
ronmental and epigenetic factors also play a critical role in the 
etiology of the disease (5, 43, 44). Previous studies have shown 
differences in genetic associations with GD in different ethnic 
groups; however, most of these studies compared Caucasian 
patients to Asian patients.
In the present study, we dissected the genetic susceptibility in 
GD patients of Italian origin via fine mapping the Italian GD locus 
on chromosome 3q and analyzing several known susceptibility 
genes for GD. We identified three SNPs on chromosome 3q that 
were associated with GD in Italian patients, and we demonstrated 
that the TSHR, the CTLA-4, and the TG genes are associated with 
GD in Italians. Our results are consistent with previous findings 
suggesting the existence of unique autoimmunity susceptibility 
genes in Caucasian populations of different geographic regions 
(26, 45). Indeed, Marron et al. have shown considerable variability 
FigUre 1 | Fine mapping analysis of the locus on chromosome 3q that showed strong linkage with gD in our subset of italian gD families. The locus 
spans approximately 14 Mb and was fine mapped using a panel of 690 informative SNPs. The X-axis shows the distance in base pair between the SNPs and the 
Y-axis shows the −log(p-value) as computed by the UNPHASED program. The red line corresponds to a p-value of 0.01. Three SNPs (rs13097181, rs7633131, and 
rs6792646) showed significant association with p-values <0.01.
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in the association of CTLA-4 with type 1 diabetes among different 
Caucasian populations (46).
We tested 690 SNPs for association with GD at the 3q locus, 
a locus which a family study had previously been identified as 
containing a GD-related gene. Our goal in this study was not to 
identify a region containing disease-related gene but to prioritize 
which genes might be worth pursuing. Many of the 690 SNPs 
we typed shared LD blocks, meaning the association signals the 
SNPs produced were not independent of one another. The 3q 
locus that was fine mapped contained 124 LD blocks. Correcting 
for multiple testing using the Bonferroni correction for 124 tests 
would make the p-values for the three associated SNPs become 
not significant. However, since we were within a locus that we 
already determined to be linked to the disease, interpreting the 
Bonferroni-corrected p-values with the same intent as for a GWAS 
would miss our goal of determining which genes would be the 
best ones to examine in the next step of identifying the disease-
related gene. Ideally, stronger association signals (p-values) 
would be better but the decision to investigate a specific patient 
population limited the sample size. Nonetheless, the results do 
give us important information that can be used to prioritize the 
known genes best supported by our association study.
The SNP within the chromosome 3q locus showing the 
strongest association with GD in Italians (rs13097181) maps to 
an intergenic region between the EPHB1 gene (ephrin receptor B 
1) and the KY gene (kyphoscoliosis peptidase). Notably, ephrin 
receptors make up the largest subgroup of the receptor tyrosine 
kinase family and are known to regulate T-cell activation, 
costimulation, and proliferation (47, 48), suggesting a potential 
functional role for EPHB1 in the context of GD pathogenesis. 
The potential role, if any, of the KY gene, generally involved in 
processes of muscle growth (49), in GD pathophysiology remains 
to be determined. The other two chromosome 3q SNPs that 
were associated with GD in our population are rs7633131 and 
rs6792646. rs7633131 is an intronic SNP within the CLSTN2 gene 
(calsyntenin 2), which does not affect the immune system or the 
thyroid (50). rs6792646 is an intergenic SNP located between 
the GRK7 (G protein-coupled receptor kinase 7) gene and the 
HMGN2P25 (high mobility group nucleosomal-binding domain 
2 pseudogene 25) gene, two genes that do not seem to be func-
tionally connected to GD (51, 52). Of course, the assumptions on 
potential mechanisms linking these genes to GD deserve further 
experimental validation. Nonetheless, disease-associated SNPs 
can also impact transcriptional mechanisms by modulating the 
binding of transcriptional factors or long-range interactions via 
genetic/epigenetic dysregulation (43, 53), eventually upregulat-
ing or downregulating gene transcription in order to generate a 
phenotype (54).
Genes that exert their effect early in the autoimmune 
response and control the breakdown in self-tolerance are 
strongly associated with GD. In the past two decades, several 
GD susceptibility genes have been identified and confirmed 
through linkage and association studies, including HLA-DRβ1-
Arg74, CTLA-4, PTPN22, CD40, CD25, TG, and the TSHR gene 
(55). TG, in particular, is an important candidate gene for GD, 
indeed the best model of human autoimmune thyroiditis is 
induced by immunizing mice with TG (56). Interestingly, GD 
patients have increased numbers of circulating T cells and B 
TaBle 1 | results of candidate gene analysis.
candidate gene snP p-value
IL23R rs2201841 0.622036
IL23R rs11209026 0.259565
IL23R rs10889677 0.786908
PTPN22 rs2476601 0.727479
cTla4 rs231775 0.00106852
cTla4 rs3087243 0.0303233
IRF5 rs4728142 0.45456
IRF5 rs10488631 0.769101
IRF5 rs12537284 0.56248
Tg rs180194 0.384458
Tg rs180223 0.624968
Tg rs2069550 0.692976
Tg rs853326 0.754905
Tg rs2069561 0.0292331
Tg rs2076740 0.182472
Tg rs2294024 0.214108
TLR4 rs4986790 0.736433
TLR4 rs4986791 0.163881
CD25 rs706778 0.0630883
CD25 rs3118470 0.52791
CD25 rs41295061 0.498702
Tshr rs179247 3.94e−06
Tshr rs3783948 0.00104205
Tshr rs12101255 0.0356936
CD40 rs1883832 0.464766
CD40 rs4810485 0.466903
FOXP3 rs6609857 0.743244
FOXP3 rs2294021 0.703636
FOXP3 rs2280883 0.747625
FOXP3 rs2232365 0.738291
FOXP3 rs3761549 0.496996
Genes in bold are significantly associated with GD.
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cells that proliferate in response to stimulation with TG (57). 
Recently, a significant positive correlation has been reported 
between serum TG levels and the presence and severity of oph-
thalmopathy in patients with GD. In these patients, TG levels 
also correlated to serum titers of TSHR antibodies, indicating 
that not only TSHR but also TG may be released from the thy-
roid gland in the course of a thyroiditis and home to the orbit 
where they become targets of autoantibodies and cytotoxic T 
lymphocytes (58, 59).
Furthermore, several genetic studies have demonstrated an 
association between thyroid autoimmunity and gene polymor-
phisms of proteins and enzymes associated with vitamin D 
functions (60–62). Indeed, in animal models, vitamin D 
administration efficiently prevented the induction of experimen-
tal autoimmune thyroiditis (63). Moreover, taking into account 
human studies, a high prevalence of vitamin D deficiency was 
reported both in patients with chronic autoimmune thyroiditis 
and in those with GD (64).
Consistent with previous reports (5, 40), among the candidate 
genes we tested, we found significant associations with the TSHR, 
CTLA-4, and TG genes. The CTLA-4 gene had been previously 
implicated, in different ethnic groups, in diverse autoimmune 
disorders, including Addison’s disease (65), Hashimoto’s thy-
roiditis (66), Type 1 diabetes mellitus (22), multiple sclerosis 
(67), and GD (68). Of note, there was no significant association 
of GD with CD40 in our dataset, which is in agreement with our 
previous finding that CD40 was not linked with GD in a cohort 
of Italian families (69). Moreover, the TG SNP that is associated 
with GD in our Italian cohort is different than the one we previ-
ously identified in a cohort of North American Caucasian AITD 
patients, again underscoring the importance of ethnic variations 
in variants predisposing to GD.
The main limitation of our study is the relatively small size 
of our cohort. However, our cohort was ethnically homogenous, 
thereby increasing the power of our analysis.
In conclusion, we identified three SNPs on chromosome 3q 
that are associated with GD in Italian patients indicating potential 
GD susceptibility genes in this locus. Furthermore, we demon-
strated that the TSHR, the CTLA-4, and the TG genes are associ-
ated with GD in Italians. Notably, there were no associations with 
CD40, CD25, and FOXP3. Our findings highlight the importance 
of ethnic variation in the association of different polymorphisms 
with GD even within the same candidate gene.
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